Lake Street initiated coverage on SWK Holdings with a new price target
$SWKH
Diversified Financial Services
Finance
Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/28/2022 | $26.00 | Buy | Lake Street |
| 4/18/2022 | $26.00 | Buy | Lake Street |
Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00
Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00
4 - SWK Holdings Corp (0001089907) (Issuer)
4 - SWK Holdings Corp (0001089907) (Issuer)
4 - SWK Holdings Corp (0001089907) (Issuer)
Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi
Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin
New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv
425 - SWK Holdings Corp (0001089907) (Subject)
425 - SWK Holdings Corp (0001089907) (Subject)
425 - SWK Holdings Corp (0001089907) (Subject)
Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists
Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC
Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi
Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results
SC 13G/A - SWK Holdings Corp (0001089907) (Subject)
SC 13D/A - SWK Holdings Corp (0001089907) (Subject)
SC 13G/A - SWK Holdings Corp (0001089907) (Subject)